Citigroup Inc. reaffirmed their buy rating on shares of PerkinElmer, Inc. (NYSE:PKI) in a report released on Tuesday. The brokerage currently has a $80.00 price target on the medical research company’s stock, up from their prior price target of $74.00.

Other equities analysts have also issued reports about the stock. Jefferies Group LLC reiterated a hold rating and issued a $69.00 target price (up from $58.00) on shares of PerkinElmer in a report on Tuesday, June 20th. Cantor Fitzgerald reiterated a hold rating on shares of PerkinElmer in a report on Sunday, July 16th. BidaskClub lowered shares of PerkinElmer from a strong-buy rating to a buy rating in a report on Wednesday, June 14th. Piper Jaffray Companies reiterated a buy rating and issued a $81.00 target price on shares of PerkinElmer in a report on Friday, August 4th. Finally, Cowen and Company reiterated a market perform rating and issued a $70.00 target price (up from $61.00) on shares of PerkinElmer in a report on Tuesday, June 20th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the company’s stock. PerkinElmer has a consensus rating of Hold and an average target price of $67.92.

PerkinElmer (PKI) traded up 0.92% during mid-day trading on Tuesday, reaching $68.97. 432,077 shares of the company were exchanged. The company has a market capitalization of $7.60 billion, a price-to-earnings ratio of 20.80 and a beta of 0.74. The company has a 50 day moving average of $66.08 and a 200-day moving average of $63.21. PerkinElmer has a 1-year low of $45.35 and a 1-year high of $70.16.

PerkinElmer (NYSE:PKI) last posted its earnings results on Thursday, August 3rd. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. The company had revenue of $547.00 million for the quarter, compared to analyst estimates of $554.14 million. PerkinElmer had a net margin of 16.80% and a return on equity of 13.44%. PerkinElmer’s revenue was up 2.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.67 EPS. On average, equities research analysts forecast that PerkinElmer will post $2.89 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/30/perkinelmers-pki-buy-rating-reaffirmed-at-citigroup-inc.html.

The business also recently declared a quarterly dividend, which will be paid on Friday, November 10th. Stockholders of record on Friday, October 20th will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.41%. The ex-dividend date of this dividend is Thursday, October 19th. PerkinElmer’s dividend payout ratio (DPR) is 8.46%.

Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of PerkinElmer by 2.6% in the 2nd quarter. Vanguard Group Inc. now owns 10,886,642 shares of the medical research company’s stock valued at $741,816,000 after acquiring an additional 273,975 shares during the period. Janus Henderson Group PLC purchased a new stake in shares of PerkinElmer in the 2nd quarter valued at approximately $436,483,000. BlackRock Inc. raised its stake in shares of PerkinElmer by 2.4% in the 2nd quarter. BlackRock Inc. now owns 5,929,277 shares of the medical research company’s stock valued at $404,022,000 after acquiring an additional 141,650 shares during the period. State Street Corp raised its stake in shares of PerkinElmer by 2.2% in the 1st quarter. State Street Corp now owns 3,875,455 shares of the medical research company’s stock valued at $225,011,000 after acquiring an additional 82,817 shares during the period. Finally, Primecap Management Co. CA raised its stake in shares of PerkinElmer by 0.7% in the 1st quarter. Primecap Management Co. CA now owns 3,531,955 shares of the medical research company’s stock valued at $205,065,000 after acquiring an additional 25,825 shares during the period. 91.47% of the stock is currently owned by institutional investors and hedge funds.

PerkinElmer Company Profile

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Analyst Recommendations for PerkinElmer (NYSE:PKI)

Receive News & Stock Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related stocks with our FREE daily email newsletter.